<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04891484</url>
  </required_header>
  <id_info>
    <org_study_id>MS.20.09.1248</org_study_id>
    <nct_id>NCT04891484</nct_id>
  </id_info>
  <brief_title>Effect of Ondansetron on Spinal-induced Hypotension for Percutaneous Nephrolithotomy</brief_title>
  <official_title>Effect of Ondansetron on Spinal-induced Hypotension by Using Bupivacaine -Dexmedetomidine Mixture Intrathecally for Percutaneous Nephrolithotomy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mansoura University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mansoura University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Percutaneous nephrolithotomy (PCNL) is the surgical standard for treating large or complex&#xD;
      renal stones. The stones are removed by passing a small telescope through the side of the&#xD;
      patient directly into the kidney, so the stone can be broken up and the fragments are removed&#xD;
      .PCNL can be performed under general anesthesia or spinal anesthesia. SA has some advantage&#xD;
      over GA, such as lower postoperative pain, lower consumption of analgesic drugs and avoidance&#xD;
      of side effects from multiple medications used in GA.However, SA induced sympathetic block&#xD;
      leads to a decrease in the systemic vascular resistance and subsequent drop in the arterial&#xD;
      blood pressure. Furthermore, anesthesia for PCNL usually requires a high sensory level&#xD;
      reaching T4,resulting in a high incidence (nearly 33%) of hypotension. Also, to meet the long&#xD;
      duration of surgery, drugs, ;like dexmedetomidine, are added to intrathecal local anesthetics&#xD;
      , increasing the incidence of hemodynamic instability induced by the spinal anesthesia.&#xD;
&#xD;
      Decreasing the systemic vascular resistance (SVR) and the venous return to the heart result&#xD;
      in a reflex vasodilation, bradycardia and hypotension. This reflex is called Bezold -Jarisch&#xD;
      reflex and is mediated by serotonin receptors (5_HT3) located on the vagus nerve and within&#xD;
      the wall of the cardiac ventricles.&#xD;
&#xD;
      Ondansetron; an antiemetic drug used for treatment of perioperative nausea and vomiting, was&#xD;
      investigated as a 5HT antagonist for inhibition of Bezold - Jarisch reflex. While some&#xD;
      studies proved its efficacy in prevention of spinal anesthesia induced hypotension , other&#xD;
      studies could not support this conclusion .&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study aims to assess the effect of Ondansetron on spinal induced hypotension when&#xD;
      bupivacaine and dexmedetomidine are used intrathecally during spinal anesthesia for&#xD;
      percutaneous nephrolithotomy.This prospective randomized double-blinded study will be carried&#xD;
      out at Urology and Nephrology center, Mansoura University after approval of Institutional&#xD;
      Research Board, Faculty of Medicine, Mansoura University. Written informed consents will be&#xD;
      obtained from participants after explanation of the used drug and its possible consequences.&#xD;
&#xD;
      Basal readings for blood pressure, heart rate, and ECG analysis and oxygen saturation will be&#xD;
      recorded before the start of spinal anesthesia.&#xD;
&#xD;
      Upon arrival to OR, wide bore intravenous access (20 gauge cannula) will be secured for&#xD;
      preoperative fluid preloading (10 ml/kg ringer solution intravenously).All patients will be&#xD;
      monitored for non-invasive blood pressure (BP), Heart rate (HR) , ECG and pulse oximetry ,&#xD;
      measurements will be recorded every 5 min for first 30 minutes then every 15 min till the end&#xD;
      of surgery .Patients will be randomly divided into two groups, using a computer generated&#xD;
      random table;&#xD;
&#xD;
        -  Group S:patients will be injected with 10 ml normal saline intravenous 5 min before&#xD;
           spinal anesthesia&#xD;
&#xD;
        -  Group O:patients will be injected with 4mg Ondansetron diluted with normal saline IV 5&#xD;
           minutes before spinal anesthesia Spinal anesthesia will be delivered in the sitting&#xD;
           position under complete aseptic condition using 25-gauge spinal needle (quinckle type),&#xD;
           the needle will be advanced at level L 4-5 or L 3 - 4. After a clear flow of CSF, 3ml&#xD;
           0.5 % hyperbaric bupivacaine (15mg)will be injected followed by 5 Mcg dexmedetomidine in&#xD;
           insulin syringe diluted to 1ml .After anesthesia, patients will be positioned supine&#xD;
           immediately, sensory level will be assessed each 2 minutes by pinprick test, a sensory&#xD;
           block at T4-6 will be considered sufficient to start surgery.o BP, HR and oxygen&#xD;
           saturation will be recorded every 5 minutes for first 30 minutes then every 15 minutes&#xD;
           till the end of surgery. Hypotension will be defined as a decrease blood pressure more&#xD;
           than 20% of basal BP or decrease systolic than 90 mmHg and will be treated with IV&#xD;
           ephedrine (5mg bolus). Bradycardia will be defined as heart rate less than 50 beat / min&#xD;
           and will be treated with IV atropine (0.5mg).The maximum level of sensory block will be&#xD;
           assessed every 2 minutes till reaching maximum level of sensory block by pin prick test&#xD;
           or cold sensation using alcohol swab.The incidence of ECG changes(dysrhythmia, ST&#xD;
           changes).The incidence of pruritus.The incidence of nausea and /or&#xD;
           vomiting.Postoperative data( HR, BP, SPo2) will be measured every 15 minutes for 2&#xD;
           hours.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 1, 2012</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">October 1, 2021</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Two groups were enrolled in this study. They will randomized into two groups •Group S:patients will be injected with 10 ml normal saline intravenous 5 min before spinal anesthesia •Group O:patient swill be injected with 4 mg Ondansetron diluted with normal saline IV 5 minutes before spinal anesthesia</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Investigator, Outcomes Assessor)</masking>
    <masking_description>Double-blinded</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>The incidence of hypotension during spinal anesthesia for percutaneous nephrolithotomy</measure>
    <time_frame>perioperative time for two hours postoperatively</time_frame>
    <description>The incidence of hypotension with mean pressure below 60 mmhg during spinal anesthesia for PCNL</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The severity of hypotension</measure>
    <time_frame>perioperative time for two hours postoperatively</time_frame>
    <description>The severity of hypotension with mean blood pressurer either mild (less than 60 mmHg), or moderate(less than50 mmHg or severe (less than 40mmHg)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The duration and number of hypotension episodes</measure>
    <time_frame>perioperative time for two hours postoperatively</time_frame>
    <description>The duration of each hypotension episode</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The need of vasopressors (ephedrine and noradrenaline) .</measure>
    <time_frame>perioperative time for two hours postoperatively</time_frame>
    <description>The need and the dose of vasopressors (ephedrine and noradrenaline) .</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The incidence of bradycardia Intraoperative</measure>
    <time_frame>perioperative time for two hours postoperatively</time_frame>
    <description>The incidence of bradycardia Intraoperative</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The incidence of perioperative nausea and vomiting</measure>
    <time_frame>perioperative time for two hours postoperatively</time_frame>
    <description>The incidence of perioperative nausea and vomiting</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The incidence of perioperative shivering</measure>
    <time_frame>perioperative time for two hours postoperatively</time_frame>
    <description>The incidence of perioperative shivering</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The incidence of perioperative pruritus</measure>
    <time_frame>perioperative time for two hours postoperatively</time_frame>
    <description>The incidence of perioperative pruritus</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Percutaneous Nephrolithotomy</condition>
  <arm_group>
    <arm_group_label>Ondansetron group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group O :patients will be injected with 4 mg Ondansetron diluted with normal saline IV 5 minutes before spinal anesthesia</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Group S:patients will be injected with 10 ml normal saline intravenous 5 min before spinal anesthesia</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ondansetron group</intervention_name>
    <description>patients will be injected with 4 mg Ondansetron diluted with normal saline IV 5 minutes before spinal anesthesia</description>
    <arm_group_label>Ondansetron group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saline group</intervention_name>
    <description>patients will be injected with 10 ml normal saline intravenous 5 min before spinal anesthesia</description>
    <arm_group_label>Control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients scheduled for PCNL surgery.&#xD;
&#xD;
          2. ASA classification I or II&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patient refusal&#xD;
&#xD;
          2. Contraindication to spinal anesthesia.&#xD;
&#xD;
          3. Known allergy to Ondansetron.&#xD;
&#xD;
          4. Uncontrolled hypertensive patient.&#xD;
&#xD;
          5. Ischemic heart diseases.&#xD;
&#xD;
          6. Moderate to severe stenotic valve lesion.&#xD;
&#xD;
          7. Atrial fibrillation.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mahmoud M Othman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of anesthesia ,Urology and nephrology center ,Faculty of medicine,Mansoura university</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mahmoud M Othman, MD</last_name>
    <phone>00201006278070</phone>
    <email>mmothman59@hotmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mohamed F Elnagar, BCH</last_name>
    <phone>00201284168188</phone>
    <email>elnagarmohammad552@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Urology and nephrology center</name>
      <address>
        <city>Mansoura</city>
        <state>Dakahlia</state>
        <zip>050</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mahmoud M Othman, MD</last_name>
      <phone>00201006278070</phone>
      <email>mmothman59@hotmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Mohamed F Elnagar, BCh</last_name>
      <phone>00201284168188</phone>
      <email>elnagarmohammad552@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Enas A Abdelmotalb, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Elrefay A Khandil, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 10, 2021</study_first_submitted>
  <study_first_submitted_qc>May 13, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 18, 2021</study_first_posted>
  <last_update_submitted>May 13, 2021</last_update_submitted>
  <last_update_submitted_qc>May 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mansoura University</investigator_affiliation>
    <investigator_full_name>Mahmoud Mahmoud Othman</investigator_full_name>
    <investigator_title>Professor of anesthesia and surgical Intensive care</investigator_title>
  </responsible_party>
  <keyword>Ondansetron, hypotension,vasopressor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypotension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ondansetron</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

